A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs VIB-7734 (Primary)
- Indications Dermatomyositis; Poliomyelitis; Sclerosis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors MedImmune
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 Planned End Date changed from 13 Aug 2018 to 3 Jul 2018.
- 14 Sep 2017 Planned primary completion date changed from 6 Nov 2017 to 23 Oct 2017.